Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 55 EUR
  • 25 mg - 220 EUR
  • 100 mg - 660 EUR

Vemurafenib

Vemurafenib is a BRAF inhibitor approved for the treatment of late-stage melanoma and for the treatment of adult patients with BRAF V600E unresectable or metastatic melanoma. In preclinical models, vemurafenib inhibited the growth of BRAF V600E-positive melanoma cell lines both in vitro and in vivo. Purified kinase assays have demonstrated that PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase.

catalogue number: V156
synonyms: PLX4032, RG7204, RO5185426, Zelboraf
CAS: 918504-65-1
MW: 489.92 g/mol

References
Curr Opin Investig Drugs. 2010 Jun;11(6):699-706. PMID: 20496265
Cancer Res. 2010 Jul 1;70(13):5518-27. PMID: 20551065